Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals in metadata) on September 5, 2018. The filing serves to disclose an updated investor presentation (Exhibit 99.1) intended for use at the H.C. Wainwright 20th Annual Global Investment Conference held September 4-6, 2018, in New York City. The Company is an emerging growth company incorporated in Delaware.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a presentation exhibit rather than a financial statement.
Material Changes
No material financial changes versus prior periods are reported in this text. The primary event is the furnishing of an updated investor presentation for an upcoming conference presentation by CEO Stephen From.
Guidance, Outlook, and Risks
- Management Commentary: The CEO, Stephen From, is scheduled to present at the H.C. Wainwright conference on September 6, 2018.
- Regulatory Status: The information furnished, including the attached presentation, is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated.
- Forward-Looking Statements: The Company explicitly states it does not assume any obligation to update the information or exhibit in the future.
Key Facts for Investor Verification
- Verify the content of the attached Exhibit 99.1 (Investor Presentation) for specific financial data and strategic updates, as this 8-K only references the document.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the presentation materials are not legally "filed" and the Company has disclaimed any obligation to update them.